Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cameron Stephenson

Nurse Practitioner, Acute Care Birmingham, AL Nurse Practitioner

NPI 1174080402 CMS profile 11019438

3686 Grandview Pkwy Ste 600, Birmingham, AL 35243

Open in the dashboard

General payments

$13,447

522 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cameron Stephenson of Birmingham, AL is reported in the CMS Open Payments database as having received $13,447 across 522 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,569 82
2024 General $4,274 176
2023 General $2,823 109
2022 General $2,214 79
2021 General $1,567 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cameron Stephenson
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Cameron Stephenson were reported at $2,569. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Cameron Stephenson Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,567 $123 $38–$327 $132
2022 $2,214 $130 $44–$369 $149
2023 $2,823 $144 $49–$410 $160
2024 $4,274 $146 $48–$433 $164
2025 $2,569 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,519 80 payments
  2. Alexion Pharmaceuticals, Inc. $1,392 35 payments
  3. Neurocrine Biosciences, Inc. $1,109 32 payments
  4. UCB, Inc. $1,037 38 payments
  5. AbbVie, Inc. $854 60 payments
  6. Teva Pharmaceuticals USA, Inc. $573 17 payments
  7. Lilly USA, LLC $560 34 payments
  8. Argenx US, Inc. $474 15 payments
  9. Lundbeck LLC $380 16 payments
  10. SK Life Science, Inc. $379 16 payments
  11. Other $5,169 179 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,413 519 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32 2 payments
  3. Education $2 1 payment
Products named General payments · program years 2021–2025
  1. KESIMPTA Neurology $1,138 58 payments
  2. INGREZZA $1,109 32 payments
  3. ULTOMIRIS $705 25 payments
  4. Briviact $426 18 payments
  5. Rystiggo $414 14 payments
  6. VYEPTI $335 14 payments
  7. Leqembi $334 14 payments
  8. AJOVY $333 14 payments
  9. KESIMPTA Neuroscience $326 19 payments
  10. MAYZENT $326 19 payments
  11. Other $7,725 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record